2-(4-甲氧基苯基)-1H-吲哚 | 63834-14-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻嗪类
• 中文名称: 2-(4-甲氧基苯基)-1H-吲哚
• 英文名称: 10-<1-Methyl-piperidyl-(4)>-phenothiazin.
• 英文别名: 10-(1-methyl-piperidin-4-yl)-10H-phenothiazine；10-(1-methyl-[4]piperidyl)-phenothiazine；10-(1-Methyl-[4]piperidyl)-phenothiazin；Phenothiazine, 10-(N-methyl-4-piperidyl)-；10-(1-methylpiperidin-4-yl)phenothiazine
• CAS: 63834-14-0
• 化学式: C₁₈H₂₀N₂S
• 分子量: 296.436
• InChiKey: SHIGCOJUQXBINS-UHFFFAOYSA-N

物化性质

• 沸点：
  196 °C(Press: 2-3 Torr)
• 密度：
  1.196±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  21
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  31.8
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2934300000

文献信息

• METHODS AND COMPOSITIONS FOR TREATING DEGENERATIVE AND ISCHEMIC DISORDERS
  申请人：Mootha Vamsi K.

  公开号：US20120136007A1

  公开（公告）日：2012-05-31

  Model systems have shown that shifting a cell's reliance from oxidative phosphorylation (OXPHOS) to glycolysis can protect against cell death. Exploiting the therapeutic potential of this strategy, however, has been limited by the lack of clinically safe agents that remodel energy metabolism. The present invention identifies non-toxic small molecules (e.g., drug-like compounds) that are capable of modulating oxidative metabolism. One identified compound comprises meclizine. As described herein, meclizine, and its enantiomer S-meclizine, redirects OXPHOS to glycolysis. Such compounds could be protective or therapeutic in degenerative disorders such as diabetes, Huntington's, Parkinson's, and Alzheimer's disease and/or ischemic disorders including, but not limited to, stroke, heart attack, or reperfusion injuries.

  模型系统表明，将细胞从氧化磷酸化（OXPHOS）转向糖酵解可以保护细胞免受死亡的影响。然而，利用这种策略的治疗潜力受到了缺乏临床安全制剂来重塑能量代谢的限制。本发明确定了能够调节氧化代谢的非毒性小分子（例如药物类化合物）。其中一种已确定的化合物包括美克林。如本文所述，美克林及其对映体S-美克林将OXPHOS重定向到糖酵解。这样的化合物可以在退行性疾病（如糖尿病、亨廷顿病、帕金森病和阿尔茨海默病）以及缺血性疾病（包括但不限于中风、心脏病发作或再灌注损伤）中具有保护或治疗作用。
• Methods and Compositions for Treating Degenerative and Ischemic Disorders
  申请人：The General Hospital Corporation

  公开号：US20160324850A1

  公开（公告）日：2016-11-10

  Model systems have shown that shifting a cell's reliance from oxidative phosphorylation (OXPHOS) to glycolysis can protect against cell death. Exploiting the therapeutic potential of this strategy, however, has been limited by the lack of clinically safe agents that remodel energy metabolism. The present invention identifies non-toxic small molecules (e.g., drug-like compounds) that are capable of modulating oxidative metabolism. One identified compound comprises meclizine. As described herein, meclizine, and its enantiomer S-meclizine, redirects OXPHOS to glycolysis. Such compounds could be protective or therapeutic in degenerative disorders such as diabetes, Huntington's, Parkinson's, and Alzheimer's disease and/or ischemic disorders including, but not limited to, stroke, heart attack, or reperfusion injuries.
• US9399032B2
  申请人：——

  公开号：US9399032B2

  公开（公告）日：2016-07-26